Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. (2021)
Attributed to:
MICA: Using circulating tumour DNA to identify and predict mechanisms of resistance to targeted cancer therapies.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/jnci/djaa087
PubMed Identifier: 32940689
Publication URI: http://europepmc.org/abstract/MED/32940689
Type: Journal Article/Review
Volume: 113
Parent Publication: Journal of the National Cancer Institute
Issue: 3
ISSN: 0027-8874